CURx Pharmaceuticals Announces License Agreement with Gilead Sciences

CURx Pharmaceuticals today announced it has entered into a global license agreement with Gilead Sciences, Inc. for development of Fosfomycin:Tobramycin for Inhalation (FTI) to treat Pseudomonas aeruginosa lung infection in cystic fibrosis (CF) patients. FTI is ready for Phase III clinical trials, having successfully completed … Continued

Swansea University researchers recruit seaweed in fight against infection

The disease-fighting qualities of seaweed compounds are being investigated by an international network of scientists including experts from Swansea University, Cardiff University and AlgiPharma AS with trials for new inhalation therapies for cystic fibrosis sufferers already underway. As part of a four-year … Continued

Savara Pharmaceuticals Announces FDA Grant of Qualified Infectious Disease Product (QIDP) and Fast Track Designation for Its Lead Product, AeroVanc<

Savara Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has designated the Company’s lead antibiotic product, AeroVanc, as a Qualified Infectious Disease Product (QIDP) for the treatment of persistent methicillin-resistant Staphylococcus aureus (MRSA) lung infection in cystic … Continued

Eradication of chronic methicillin-resistant Staphylococcus aureus infection in cystic fibrosis patients

Background Chronic airway infection with methicillin-resistant Staphylococcus aureus (MRSA) in patients with cystic fibrosis (CF) is an increasing clinical problem, and therapeutic options are limited. Because chronic infection with MRSA can be associated with accelerated decline in lung function, eradication … Continued